Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 43INDUSTRY 16OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Meningeal Carcinomatosis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 50Capecitabine 42apatinib 34Radiotherapy 33Oxaliplatin 33Gemcitabine 33Cyclophosphamide 32Drug Therapy 31Paclitaxel 30Carboplatin 29tislelizumab 27Irinotecan 27Fluorouracil 26Docetaxel 26Bevacizumab 23Surgical Procedures, Operative 21Nivolumab 19pembrolizumab 18fludarabine 18Radiation 16Metformin 16Exercise 16camrelizumab 15S 1 (combination) 14Control Groups 14Blood Specimen Collection 14Pemetrexed 13Standard of Care 12anlotinib 11Neoadjuvant Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × aflutinib × Clear all
NCT06643000 2025-03-06

Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Henan Cancer Hospital

Phase NA Recruiting
60 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡